



Great Yuhan, Global Yuhan



eng.yuhan.co.kr

# Yuhan Corporation

## CEO

Wook Je Cho

## Location

74, Noryangjin-ro, Daebang-dong, Dongjak-gu, Seoul, Korea

## Specialty

1. Chemical/Biologics New drug
2. Incrementally Modified Drugs

## Tel/Fax/E-mail

T. +82-2-828-0181

F. +82-2-828-0300

## CONTACT US

### Technology Transfer/ Licensing

Josephine Cho

Licensing team/Team manager

T. +82-2-828-0093

E. josephine@yuhan.co.kr

### Overseas export

Seungdoug park

Overseas Business/Team manager

T. +82-2-828-0191

E. dougpark@yuhan.co.kr

Yuhan Corporation continues to focus on innovation through breakthrough therapy R&D, new business opportunities and global network-building initiatives to grow into a leading global pharmaceutical company. Yuhan's priority lies on targeting cancer, metabolic diseases and CNS diseases. Currently, our R&D pipeline consists of 30 new drugs and 22 incrementally modified drugs (IMDs). In pursuit of breakthrough therapies, we are developing 15 oncology programs including immunotherapies and next-generation targeted drugs to fight against cancer and the best example is the newly launched Leclaza® (Lazertinib). Yuhan has incorporated an IMD-developer AddPharma in 2017, which is expected to launch range of new products and contribute to the overall sales and profit growth. Within recent years, Yuhan signed out-license deals on disc degenerative disease treatment molecule with Spine Biopharma (2018), lazertinib with Janssen (2018), two NASH treatment programs with Gilead (2019), another NASH program with Boehringer Ingelheim (2019), and a GI mobility disorder treatment molecule with Processa Pharmaceuticals (2020). These five major deals add to total of KRW 4.0 trillion in value, repositioning us as a R&D-driven pharmaceutical company with the ultimate goal of developing standard of care treatment on a global level.

## Main Products

Products	Ingredients	Indications	Exporting Countries
Rebamipide SR Tablet	Rebamipide 150mg	Gastric ulcer, Improvement of Gastric mucosal lesion	
Esomeprazole Combination Tablet	Esomeprazole, Precipitated Calcium Carbonate	Gastroesophageal Reflux Disease, Antacid	
Pregabalin SR Tablet	Pregabalin	Neuropathic pain	
Duowell Tablet	Telmisartan, Rosuvastatin	Treatment for hypertension and hyperlipidemia	Uzbekistan
Rosuampine Tablet	Amlodipine, Rosuvastatin	Treatment for hypertension and hyperlipidemia	
Rosumet SR Tablet	Metformin SR, Rosuvastatin	Antidiabetic	
Newfactan	Bovine Lung Surfactant	Treatment for respiratory distress syndrome of newborns	Vietnam, Mongolia, Bolivia
Yucla Tablet	Amoxicillin, Clavulanate Potassium	Antibiotics	
Almagate Suspension	Almagate	Antiacidic functions	
Antiplamine S Lotion	Methyl Salicylate, L-menthol	Anti-inflammatory agent	Vietnam, Malaysia
Willogel Double Action Suspension	Sodium alginate, Calcium carbonate, Sodium bicarbonate	Alleviation of heartburn and indigest	
Nazacare Nasal Spray Solution	Momethasone Furoate	Nasal symptoms of allergic rhinitis, Nasal polyps, Acute rhinosinusitis	

## R&D Pipeline

Discovery	Lead	Preclinical study	Phase 1	Phase 2	Phase 3
YHC2118 (IO)	YHC1108 (NASH)	YHC1102 (NASH)	YH25724 (NASH)	YH14618 (DDD)	LECLAZA (NSCLC)
YHC2115 (IO)	YH34160 (Obesity)	YH24931 (IO)	YH35324 (CSU)	YH12852 (FGID)	
YHC2119 (IO)	YHC1116 (Gaucher)	YH29143 (IO)			
YHC2122 (IO)	YHC1104 (NSCLC)	YH32367 (IO)			
YHC2124 (IO)	YHC1103 (IO)				
YHC1128 (IO)	YHC2120 (IO)				
YHC1125 (CNS)	YHC2126 (CNS)				
YHC2127 (CNS)					
YHC2129 (Obesity)					
YHC1131 (NASH)					

IO : Immuno-oncology  
 CNS : Central nerve system  
 NASH : Non-alcoholic steatohepatitis  
 NSCLC : Non-small cell lung cancer  
 CSU : Chronic spontaneous urticaria  
 DDD : Degenerative disk disease  
 FGID : Functional gastrointestinal disorder